Quviviq 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

quviviq

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - poruchy spánku a poruchy obsluhy - psycholeptika - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Vydura 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

vydura

pfizer europe ma eeig  - rimegepant - poruchy migrény - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Melatonin Neurim 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

melatonin neurim

rad neurim pharmaceuticals eec sarl - melatonín - poruchy spánku a poruchy obsluhy - psycholeptika - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Rayvow 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

rayvow

eli lilly nederland b.v. - lasmiditan succinate - poruchy migrény - analgetiká - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Aquipta 유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

aquipta

abbvie deutschland gmbh & co. kg - atogepant - poruchy migrény - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.